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Effect of Cardiac and Noncardiac
Conditions on Survival After Defibrillator Implantation
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Objectives We sought to examine outcomes in recipients of implantable cardioverter-defibrillators (ICDs) and the effect of
age, gender, and comorbidities on survival.
Background Age, gender, and comorbidities may significantly affect outcomes in ICD recipients.
Methods We examined factors associated with mortality in 2,467 ICD recipients in Ontario, Canada, using a province-wide
database. Comorbidities were identified retrospectively by examining all diagnosis codes within the 3 years be-
fore implant.
Results Mean ages at ICD implant were 63.2  12.5 years (1,944 men) and 59.8  15.9 years (523 women). Mortality
rates at one and 2 years were 7.8% and 14.0%. Older age at implant increased the risk of death with hazard
ratios (HR) of 2.05 (95% confidence interval [CI] 1.70 to 2.47) and 3.00 (95% CI 2.43 to 3.71) for those 65 to
74 years and 75 years, respectively (both p  0.001), but gender was not a predictor of death. Common non-
cardiac conditions associated with death included peripheral vascular disease (adjusted HR 1.50, 95% CI 1.18
to 1.91), pulmonary disease (adjusted HR 1.35, 95% CI 1.10 to 1.66), and renal disease (adjusted HR 1.57,
95% CI 1.25 to 1.99). Many ICD recipients had prior heart failure (46.2%) with an increased HR of 2.33 for
death (95% CI 1.96 to 2.76; p  0.001). Greater comorbidity burden conferred increased risk, with HRs adjusted
for age, gender, and heart failure of 1.72 (95% CI 1.44 to 2.05), 2.79 (95% CI 2.15 to 3.62), and 2.98 (95% CI
1.74 to 5.10) for those with 1, 2, and 3 or more noncardiac comorbidities, respectively (all p  0.001).
Conclusions Age, noncardiac comorbidities, and prior heart failure influence survival outcomes in ICD recipients. These fac-
tors should be considered in the care of ICD recipients. (J Am Coll Cardiol 2007;49:2408–15) © 2007 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.058a
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rhe implantable cardioverter-defibrillator (ICD) has been
emonstrated to be highly efficacious in randomized con-
rolled trials of patients at risk of ventricular tachyarrhyth-
See page 2416
ias by providing rapid identification and treatment of
otentially lethal rhythm disturbances. The devices are
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Manuscript received November 9, 2006; revised manuscript received January 26,
007, accepted February 27, 2007.ppealing because they provide early defibrillation for life-
hreatening ventricular tachyarrhythmias, resulting in long-
erm survival that is associated with preserved quality of life
1). Landmark randomized controlled trials of ICDs have
emonstrated reductions in arrhythmic death and all-cause
ortality in patients receiving ICD therapy (2–5).
Interventions that have been shown to reduce mortality
n randomized controlled trials have often had attenuated
enefits in population-based studies because of the dif-
erences between community-based patients and the
ften highly selected individuals enrolled in randomized
rials. For example, studies of community-based patients
ith heart failure (HF) and myocardial infarction have
eported disparities in patient characteristics and mortal-
ty (6). These disparities have been attributed partly to
ifferences in age and comorbidity burden, which may
ontribute to a greater risk of competing events that may
educe overall effectiveness of treatments in unselected
atients (7).
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June 26, 2007:2408–15 Predictors of Survival After Defibrillator ImplantIn response to the widening indications for ICDs, there
ave been calls for better stratification methods to identify
isk groups that would most benefit, or that would be
nlikely to benefit, from the device (8–11). Analysis of
omorbidities may help identify subsets that are most likely
o benefit from the ICD. Information about survival after
CD insertion in real-world samples, and the impact of age,
ender, and comorbidities on outcomes, has not been previ-
usly assessed. In the present study, we hypothesized that HF
nd noncardiac conditions would be associated with higher
ortality rates and could potentially aid in identifying those
ho would benefit less from ICD insertion.
ethods
tudy sample. We identified patients who underwent ICD
mplantation in Ontario, Canada, from April 1, 1997, to
arch 31, 2003, using the Canadian Institute for Health
nformation (CIHI) discharge abstract and same-day sur-
ery databases. The CIHI database contains information on
ll hospital separations and cardiac procedures, and the
ame-day surgery database contains data on procedures
erformed on outpatients. Patients undergoing implanta-
ion of the ICD and dates of implantation were identified
sing Canadian Classification of Procedures code 49.74,
nd International Classification of Diseases, version 10
ICD-10), codes 1HZ53GRFS and 1HZ53LAFS. These
odes are used by Ontario hospitals where electrophysiology
ervices are provided and ICDs are implanted.
To identify first ICD implants, we excluded those who
ad a prior procedure within 10 years before the index
mplantation date. We also excluded patients who were18
ears or 105 years of age at the time of ICD implant,
onresidents, and those with an invalid health card number.
urvival information was obtained up to the last follow-up
ate, March 31, 2005, from the Registered Persons Data-
ase of vital statistics. We compared the survival of ICD
ecipients with control subjects selected from the Registered
ersons Database, who were alive in the year that the
atched ICD patient underwent device implantation. In
ddition, control subjects were matched according to age (2
ears), prior arrhythmia (e.g., ventricular tachycardia [VT],
ardiac arrest, ventricular fibrillation [VF], or none), prior HF,
nd number of significant comorbidities identified on the basis
f the multivariable regression analysis to optimally match
CD recipients with control device nonrecipients.
omorbidities. Comorbidities present before ICD inser-
ion were identified from the secondary diagnosis fields of
he CIHI database, and were classified into the categories of
he Deyo-Charlson comorbidity classification system (12).
pecific diagnoses were identified according to the Interna-
ional Classification of Diseases coding system, version 9
ICD-9) (13) or version 10 (14) using previously published
ethods (15). We identified prior arrhythmia history by the
iagnosis of cardiac arrest (ICD-9 code 427.5, ICD-10
ode I46), VF (ICD-9 code 427.4, ICD-10 code I490), and eT (ICD-9 code 427.1, ICD-10
ode I472). Patients with prior
yocardial infarction were iden-
ified by ICD-9 codes 410 and
12 or ICD-10 codes I21, I22,
nd I25.2, and those with HF
ere identified by ICD-9 code
28 or ICD-10 code I50. Those
ith ischemic heart disease were
dentified by ICD-9 codes 411 to
14, or ICD-10 codes I20, I22,
24, and I25.
To enhance sensitivity for the
resence of all chronic comorbid
onditions and arrhythmia, we
xamined all secondary diagnosis
ata during the ICD implant
dmission, and all primary and
econdary diagnoses from hospitalization data occurring 3
ears before the date of ICD implant. Analysis of comor-
idities was performed by modeling each group of cardiac
nd noncardiac conditions as independent model covariates.
tatistical analysis. We examined the frequency of cardiac
onditions and noncardiac comorbidities in ICD recipients
nd unadjusted 1- and 2-year mortality rates. The mortality
ffects of gender and age were modeled by grouping age into
he following categories: 18 to 64 years, 65 to 74 years, and
75 years. Variables associated with mortality after ICD
nsertion were evaluated using Cox proportional hazards
egression analysis. Initially, we examined the effects of age,
ender, the contribution of prior cardiac arrhythmia, and
he Deyo-Charlson comorbidity score, followed by univari-
te Cox analysis of the mortality effects of individual
omorbidities. In the latter analysis, comorbidities were
ategorized according to the moieties of the Deyo-Charlson
lassification, a widely adopted comorbidity index applicable
o administrative databases (12). Multivariable analysis was
erformed to identify comorbidities significantly associated
ith mortality using backward elimination, retaining covari-
tes significant at a p  0.05 level. We assessed the effect of
ge continuously after adjustment for gender and all signif-
cant comorbidities on multivariable analysis using a cubic
pline analysis with a Cox regression model (16). We
odeled age as splines with knots at the 5th, 27.5th, 50th,
2.5th, and 95th percentiles and tested the null hypothesis
f a linear relationship between the hazard for age and death
elative to ICD recipients at the median age.
Cox proportional hazards regression analysis was per-
ormed to determine if survival was improved in ICD
ecipients compared with control subjects after adjusting for
ge, gender, prior VT, VF, or cardiac arrest, prior HF, and
ll noncardiac comorbidities that were significant predictors
f mortality in multivariable analysis, adjusted for matching.
eparate Cox regression models were also examined for
atients with VT, VF, or cardiac arrest to determine if the
Abbreviations
and Acronyms
CI  confidence interval
HF  heart failure
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
ICD-9  International
Classification of Diseases,
version 9
ICD-10  International
Classification of Diseases,
version 10
VF  ventricular fibrillation
VT  ventricular
tachycardiaffect of ICD insertion differed in these arrhythmia sub-
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Predictors of Survival After Defibrillator Implant June 26, 2007:2408–15roups. Survival in ICD recipients was plotted using the
aplan-Meier method, and adjusted survival curves were
lotted for comparison of ICD recipients and matched
ontrols.
We performed additional analyses to better characterize
he effects of HF by examining those with a recent (occur-
ing within 6 months before ICD implant) or earlier
occurring6 months before ICD implant) event, adjusting
or age and other significant noncardiac comorbidities.
vents in the analysis included admissions for HF as the
rimary diagnosis or developed as an in-hospital complica-
ion. The effect of number of events on mortality was
etermined by categorizing patients into those with 1, 2, or
3 HF events in the 3 years before ICD insertion. All
atients had at least 2 years of follow-up and were censored
t this time unless death occurred during the follow-up
eriod. The proportional hazards assumption was tested for
ll Cox analyses. Analyses were performed using SAS
ersion 8.2 (SAS Institute, Cary, North Carolina).
esults
atient characteristics and crude mortality rates. A total
f 2,467 patients underwent first ICD implantation during
he study period, providing 4,551 person-years of follow-up.
ollow-up for mortality was determined until March 31,
005. The majority of individuals were aged65 years with
mean age of 62.5  13.4 years. Most ICD recipients were
en (1,944, 79%), who were collectively older at ICD
mplant than women (63.2  12.5 years vs. 59.8  15.9
ears, respectively). Common noncardiac conditions in-
luded diabetes and peripheral or cerebral vascular, respira-
ory, and renal disease (Table 1). There were small numbers
Demographic Characteristics of ICD Recipients
Table 1 Demographic Characteristics of ICD
Age 18–6
(n  1,1
Male gender, n (%) 899 (76
Cardiac comorbidities, n (%)
Myocardial infarction 454 (38
Ischemic heart disease 700 (59
Heart failure 501 (42
Arrhythmic conditions, n (%)
Cardiac arrest 278 (23
Ventricular fibrillation 314 (26
Ventricular tachycardia 764 (64
Any arrhythmic condition 975 (82
Noncardiac comorbidities, n (%)
Peripheral vascular disease 69 (5.8
Cerebrovascular disease 76 (6.4
Chronic obstructive pulmonary disease 123 (10
Peptic ulcer disease 8 (0.7
Renal disease 68 (5.8
Diabetes 215 (18
Diabetes with complications 34 (2.9
Nonmetastatic cancer 21 (1.8ICD  implantable cardioverter-defibrillator.f patients with dementia (n  9), rheumatologic disease
n  24), hemi/paraplegia (n  14), mild liver disease
n  5), moderate/severe liver disease (n  8), and meta-
tatic cancer (n  8) in all age categories combined (Table 1).
he median Deyo-Charlson score was 1 (25th and 75th
ercentile scores: 1, 3). The prevalence of prior arrhythmia
istory was 83%. With older age, the prevalence of noncardiac
omorbidities (peripheral vascular disease, chronic obstructive
ulmonary disease, renal disease) increased (all p trend
0.001). The overall crude mortality rates were 7.8% at 1 year
192 deaths) and 14.0% at 2 years (346 deaths).
ffect of age and gender on mortality risk. On univariate
nalysis, hazard ratios (HRs) for all-cause mortality were
.33 (95% confidence interval [CI] 1.93 to 2.81) and 3.36
95% CI 2.73 to 4.15) in those aged 65 to 74 years and75
ears relative to those 18 to 64 years, respectively (both p 
.001). The risk in men was increased relative to women
ith an HR of 1.25 (95% CI 1.02 to 1.53). The univariate
Rs for mortality in those of older age and male gender
ere attenuated when age, gender, and Deyo-Charlson
omorbidity score were included concomitantly in a multi-
ariable model. The adjusted HRs for the older age groups
5 to 74 years and 75 years were 2.05 (95% CI 1.70 to
.47) and 3.00 (95% CI 2.43 to 3.71), respectively (both
 0.001), and male gender was no longer a significant
redictor of mortality (HR 1.15, 95% CI 0.93 to 1.41).
mpact of comorbidities on mortality. The univariate and
ultivariable analyses for all-cause mortality according to
ype of comorbidity (in contrast to aggregate scores) are
resented in Table 2. Common comorbidities that were
ore likely to be associated with adverse outcome in
ultivariable analysis included HF, peripheral/cerebral vas-
e Group
ipients by Age Group
Age 65–74 yrs
(n  862)
Age >75 yrs
(n  425) p Trend
723 (83.9) 322 (75.8) 0.24
394 (45.7) 184 (43.3) 0.01
710 (82.4) 330 (77.6) 0.001
429 (49.8) 210 (49.4) 0.002
212 (24.6) 82 (19.3) 0.18
184 (21.3) 80 (18.8) 0.001
625 (72.5) 278 (65.4) 0.16
746 (86.5) 330 (77.6) 0.21
90 (10.4) 41 (9.6) 0.001
76 (8.8) 33 (7.8) 0.16
115 (13.3) 76 (17.9) 0.001
9 (1.0) 10 (2.4) 0.008
77 (8.9) 61 (14.4) 0.001
184 (21.3) 83 (19.5) 0.29
39 (4.5) 8 (1.9) 0.86
37 (4.3) 15 (3.5) 0.009by Ag
Rec
4 yrs
80)
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June 26, 2007:2408–15 Predictors of Survival After Defibrillator Implantular disease, chronic pulmonary disease, complicated or
ncomplicated diabetes, and renal insufficiency. Among the
ortality predictors in the final multivariable model
Table 2), HF was a common cardiac condition, occurring
n nearly one-half of all ICD recipients, and was associated
ith a greater than 2-fold increase in death among ICD
ecipients. The continuous effect of age on the hazard of
eath adjusted for gender and all significant comorbidities
n multivariate analysis (from Table 2) using cubic spline
nalysis is shown in Figure 1. The hazard of death increased
onlinearly, particularly after age 70 years (test for nonlin-
arity: chi-square  15.6; p  0.001).
Survival curves are shown in Figure 2 for ICD recipients
ccording to HF and comorbidity status. Compared with
CD recipients without HF or comorbidities, those with
rior HF were at increased risk of death (log rank p 
.001). The worst survival outcome was observed in ICD
ecipients with both HF and at least 1 additional model
omorbidity (log rank p  0.001). The number of addi-
ional noncardiac comorbidities (significant on multivariable
nalysis) was also associated with mortality. Relative to
hose without noncardiac comorbidities, the HRs for death
djusted for age, gender, and prior HF were 1.72 (95% CI
.44 to 2.05; p  0.001), 2.79 (95% CI 2.15 to 3.62; p 
.001), and 2.98 (95% CI 1.74 to 5.10; p 0.001) for those
ith 1, 2, and 3 noncardiac comorbidities, respectively.
Univariate and Multivariable Predictors of Death
Table 2 Univariate and Multivariable Predic
Univariate Ha
(95% C
Age 18–64 yrs Refere
Age 65–74 yrs 2.33 (1.93–
Age 75 yrs 3.36 (2.73–
Male 1.25 (1.02–
Myocardial infarction 1.29 (1.10–
Heart failure 2.69 (2.28–
Peripheral vascular disease 1.93 (1.53–
Cerebrovascular disease 1.65 (1.29–
Chronic pulmonary disease 1.85 (1.51–
Dementia 2.00 (0.75–
Renal disease 2.74 (2.21–
Rheumatologic disease 1.73 (0.92–
Diabetes 1.45 (1.21–
Microvascular complications of diabetes 3.09 (2.28–
Peptic ulcer disease 2.31 (1.34–
Mild liver disease 2.37 (0.76–
Moderate/severe liver disease 2.45 (0.92–
Cancer 2.06 (1.44–
Metastatic cancer 3.29 (1.23–
Hemi/paraplegia 1.60 (0.66–
Cardiac arrest 0.96 (0.80–
Ventricular fibrillation 0.78 (0.64–
Paroxysmal VT 1.12 (0.94–
*Covariates with hazard ratio (HR) and p values shown were included
‡HR and p value for metastatic and nonmetastatic cancer.
CI confidence interval; ICD implantable cardioverter-defibrillator
VT  ventricular tachycardia.nadjusted mortality rates for patients substratified by age,F status, and number of comorbidities are presented in
able 3.
ffect of prior arrhythmia and ICD insertion. In contrast
o the mortality associations with HF and the noncardiac
onditions described in the preceding, prior cardiac arrhyth-
ia was not associated with survival in ICD recipients.
pecifically, the presence of prior cardiac arrest, VF, or VT
as not predictive of mortality after multivariable adjust-
ent. The HRs adjusted for age, gender, HF, prior myo-
D Recipients
f Death in ICD Recipients
atio
p Value
Final Multivariable
Hazard Ratio (95% CI)* p Value
Referent
0.001 2.08 (1.73–2.51) 0.001
0.001 3.10 (2.50–3.83) 0.001
0.03 n/a
0.001 n/a
0.001 2.33 (1.96–2.76) 0.001
0.001 1.50 (1.18–1.91) 0.001
0.001 n/a
0.001 1.35 (1.10–1.66) 0.004
0.17 n/a
0.001 1.57 (1.25–1.99) 0.001
0.09 1.89 (1.01–3.53) 0.046
0.001 n/a
0.001 2.33 (1.69–3.21) 0.001
0.003 n/a
0.14 n/a
0.07 n/a
0.001 1.81 (1.29–2.54)‡ 0.001
0.02 n/a
0.29 n/a
0.68 n/a
0.009 n/a
0.20 n/a
nal multivariable model. †HR and p value for nonmetastatic cancer.
variable did not meet criteria for inclusion in the multivariable model;
Figure 1 Effect of Age on Death
Cubic spline analysis demonstrating nonlinear effect of age on death using Cox
regression adjusted for gender and significant model comorbidities. Hazard
ratios by age (solid red line) are relative to those with median age; 95% confi-
dence intervals (CI) are also shown (dotted blue lines).in IC
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Predictors of Survival After Defibrillator Implant June 26, 2007:2408–15ardial infarction, and significant noncardiac comorbidities
n ICD recipients were 0.98 (95% CI 0.79 to 1.20) for those
ith prior occurrence of cardiac arrest, 0.86 (95% CI 0.69 to
.07) for those with VF, and 0.97 (95% CI 0.82 to 1.16) for
hose with VT. The presence of these arrhythmic conditions
n combination was also not associated with mortality on
nivariate (HR 0.93, 95% CI 0.76 to 1.15) or multivariable
HR 0.89, 95% CI 0.72 to 1.10) analyses.
Control subjects with the same arrhythmia history
atched for age, prior HF, and comorbidities could be
Figure 2 Survival After ICD Insertion
by HF and Comorbidity Status
Kaplan-Meier survival plots for implantable cardioverter-defibrillator (ICD) recipi-
ents with or without heart failure (HF) and/or model comorbidities (Comorb).
The presence of prior heart failure or model comorbidity (e.g., peripheral vascu-
lar disease, chronic pulmonary disease, renal disease, rheumatologic disease,
microvascular complications of diabetes, or cancer) significantly worsened sur-
vival compared with patients who were free of these conditions (log rank p 
0.001).
Comparative Mortality Rates by Patients’ Risk C
Table 3 Comparative Mortality Rates by Pa
Age (yrs)
Recent HF Within 6 Months
Before ICD (Yes/No)
Number of Non
Comorbiditi
59 No 0
No 1
No 2
59 Yes 0
Yes 1
Yes 2
60–69 No 0
No 1
No 2
60–69 Yes 0
Yes 1
Yes 2
70 No 0
No 1
No 2
70 Yes 0
Yes 1
Yes 2
*Noncardiac comorbidities include peripheral vascular disease, chron
complications of diabetes, and metastatic or nonmetastatic cancer.
ICD  implantable cardioverter-defibrillator.dentified for 82.7% (n  2,040 pairs) of ICD recipients.
he ICD recipients had greater frequency of prior MI
39.7% vs. 34.6%), peripheral vascular disease (7.5% vs.
.7%), and renal disease (7.3% vs. 5.3%) than control
ubjects. Control subjects had more chronic obstructive
ulmonary disease (13.8% vs. 11.4%) and prior coronary
evascularization (22.2% vs. 16.9%) and were younger
mean age 62.7  13.1 years vs. 63.1  13.1 years) than
CD recipients. In multivariable Cox proportional hazards
egression analysis of all ICD recipients and control sub-
ects, no significant effect of ICDs on survival was detected,
ut there was a beneficial trend with an adjusted HR of 0.86
95% CI 0.72 to 1.02; p  0.09) among device recipients.
igure 3 shows adjusted survival curves for ICD recipients
nd control subjects with prior VT (n  1,307 pairs). In
hose with prior VT, the ICD was associated with a
ignificant increase in survival, with an adjusted HR of 0.80
95% CI 0.65 to 0.99; p  0.043). The absolute increase in
ortality in the control group at 2 years was 2% in those
ith prior VT or cardiac arrest and 1% overall. There was no
ignificant interaction of ICD recipient status with age and
omorbidities after adjustment for multiple tests.
dditional HF analyses. Relative to those without HF,
CD recipients with a recent episode of clinical HF were at
reater risk of death. Patients with a recent episode of HF
6 months before ICD implant) had an HR for mortality
f 2.98 (95% CI 2.41 to 3.69), whereas those with an event
6 months before ICD insertion had an HR for mortality
f 2.06 (95% CI 1.71 to 2.48; both p  0.001), after
djustment for age and the noncardiac comorbidities signif-
cant in multivariable analysis (Table 2). Increased number
f prior clinical HF episodes was also associated with greater
cteristics
’ Risk Characteristics
c n
(% of Overall Sample)
1-Year
Mortality (%)
2-Year
Mortality (%)
593 (24.0) 1.7 3.9
107 (4.3) 8.4 14.0
23 (0.9) 17.4 30.4
76 (3.1) 5.3 9.2
30 (1.2) 13.3 13.3
8 (0.32) 12.5 25.0
446 (18.1) 6.1 11.2
149 (6.0) 8.7 16.8
33 (1.3) 21.2 27.3
73 (3.0) 12.3 20.6
39 (1.6) 15.4 28.2
19 (0.8) 15.8 26.3
494 (20.0) 5.9 11.1
187 (7.6) 10.2 21.9
52 (2.1) 17.3 34.6
71 (2.9) 15.5 33.8
40 (1.6) 35.0 45.0
27 (1.1) 48.2 63.0
onary disease, renal disease, rheumatologic disease, microvascularhara
tients
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June 26, 2007:2408–15 Predictors of Survival After Defibrillator Implantisk of death after ICD insertion. Compared to those
ithout HF in the previous 3 years, those with 1, 2, and3
pisodes had age- and comorbidity-adjusted HRs for all-
ause death of 1.93 (95% CI 1.59 to 2.34), 2.44 (95% CI
.79 to 3.32), and 3.67 (95% CI 2.61 to 5.16), respectively
all p  0.001). The risk of death after ICD implant was
omparable for HF patients with or without prior myocar-
ial infarction, with HRs of 2.42 and 2.14, respectively
both p  0.001).
iscussion
hus far, the major sources of data for decisions related to
CDs are from randomized controlled trials. However,
andomized trial enrollees and patients in the community
ften differ substantially, in part owing to older age and
reater comorbidity burden in the latter. In the present
tudy, we found that noncardiac comorbidities were fre-
uently present in ICD recipients in a population-based
etting. The effect of age on mortality was nonlinear
hroughout the range of patient ages, and the association
ncreased in a curvilinear manner in ICD recipients who
ere older than 70 years. Comorbidities were significantly
ssociated with mortality after device implantation, but after
djustment for age there was no significant gender differ-
nce in survival. The only cardiac condition that had a
ignificant effect on mortality after ICD implant was HF.
mong the noncardiac comorbidities, renal failure, chronic
ulmonary disease, peripheral vascular disease, and diabetes
ith microvascular complications were of particular impor-
ance. Finally, the ICD was associated with a trend toward
ncreased survival overall and significantly improved survival
n those with prior VT, compared with control subjects
ithout ICDs, in analyses adjusted for age and all comor-
Figure 3 Adjusted Survival Plots
Comparison of implantable cardioverter-defibrillator (ICD) recipients and
matched control subjects (CTRL) with prior ventricular tachycardia up to 2 years
after device implantation.idity predictors of mortality. cFew studies have examined the effect of multiple comor-
idity burden on outcomes after ICD implant. In patients
ho were on dialysis, survival after ICD implant was low,
ith death occurring in nearly half of device recipients by 2
ears (17). In the Coronary Artery Bypass Graft Patch trial,
iabetes was not associated with increased mortality after
CD implant (18). In the present study, consistent results
ere observed with increased mortality in those with renal
ailure and no effect of uncomplicated diabetes. However,
e found increased mortality in those with microvascular
iabetic complications, which may indicate more severe or
ncontrolled disease. In addition, we found that a number
f other noncardiac conditions were also associated with
dverse outcomes after device implantation.
Randomized trial data have been used to identify sub-
roups with greater potential benefit from the ICD. For
xample, investigators from CIDS (Canadian Implantable
efibrillator Study) reported that patients 70 years old or
ore were more likely to benefit from ICD therapy (19).
owever, we found that older ICD recipients were more
ikely to exhibit greater comorbidity burden and increased
ortality risk despite ICD implantation. The effect of HF
everity has been examined in the randomized trial setting,
ith divergent results. In the CIDS and DEFINITE
Defibrillators in Nonischemic Cardiomyopathy Treatment
valuation) trials, patients with worse New York Heart
ssociation (NYHA) functional class derived greater ben-
fits from ICD therapy (19,20). In contrast, in the SCD-
eFT (Sudden Cardiac Death in Heart Failure Trial), the
urvival benefit of ICDs was significant in NYHA func-
ional class II HF, but there was no benefit in patients with
YHA functional class III HF (21). The present findings
re aligned with the aforementioned observations from the
CD-HeFT, because increased risk of death was observed
n ICD recipients with greater HF symptom burden as
eflected by a recent event or greater frequency of HF
ospitalization. We cannot exclude, however, that there
ay be identifiable subsets of HF patients who by virtue of
heir high baseline mortality risk may experience an absolute
enefit from ICD therapy.
Unlike pharmacologic therapies that may have pleiotropic
ffects on noncardiac organ systems (e.g., angiotensin-
onverting enzyme inhibitors), the ICD has a purely cardiac
echanism of action specific to the treatment of life-
hreatening dysrhythmias (2). The observation that prior
rrhythmia was not a significant predictor of mortality after
CD implant in part reflects the efficacy of the device in
reventing arrhythmic death and the likelihood that in the
real world” ICD recipients are likely to die of competing
omorbidities rather than arrhythmias. The present data
emonstrated lower prevalence of noncardiac conditions
han in population-based HF samples (22), suggesting that
CD recipients in Ontario during the study period were
lready selected to have a lower comorbidity burden. Other
ublished studies support this assertion, with greater relative
omorbidity burden demonstrated in ICD nonrecipients
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vident in decisions of candidacy for ICDs are likely
ultifactorial but may include empirical filtering in the
ecision-making process owing to finite quantities of
CDs available to implanting institutions or variations
mong referring physicians and electrophysiologists in
heir estimation of the ratio of risks of arrhythmic versus
onarrhythmic death (25).
The present study has important implications as health
are systems attempt to translate the broadened indications
or ICD insertion from randomized trials into clinical
ractice (5,21). First, although the ICD is effective in
educing arrhythmic death, competing noncardiac morbid-
ties are associated with increased mortality in ICD recipi-
nts and may affect outcomes of these patients in the “real
orld” setting. Second, although older age has been sug-
ested as a means of identifying those who would benefit
rom the ICD, it is also strongly associated with mortality
fter ICD implant. Therefore the decision to implant based
n patient age could lead to greater comorbidity burden and
ower impact of the ICD on all-cause mortality in the
opulation. Finally, because clinical HF was an important
eterminant of outcome, examination of other factors asso-
iated with HF outcomes may also be worthy of further
xamination in future studies of risk stratification in ICD
andidates. The implications of HF in ICD recipients are
urther magnified because the life-prolonging benefit of ICD
herapy is associated with an increase in HF events over time
26). To the clinician contemplating ICD insertion for a given
atient, age and the presence or absence of chronic diseases are
argely unmodifiable. The present findings suggest, therefore,
hat it is both a personal and societal decision about how high
he risk of death from competing causes should be before an
CD is no longer justified.
tudy limitations. The present study was limited by the
ack of clinical information on left ventricular function,
nducibility and severity of ventricular tachyarrhythmias,
nd other clinical variables that may influence HF-specific
utcomes. Determinations of cardiac conditions and comor-
idities were based on administrative data sources which
ay be undercoded. However, prior analysis of administra-
ive comorbidities suggests high degree of specificity com-
ared with primary chart records (27). Similarly, further
linical characterization of comorbidities (e.g., subclassifi-
ation of prior cardiac arrest due to bradyasystolic or
achyarrhythmic events) and modes or causes of death could
ot be performed. Unlike the control subjects in the present
nalyses, the follow-up of ICD recipients occurs on a
egularly scheduled basis, and therefore differences in med-
cal management between the 2 groups could have occurred
ver time. However, this would not have resulted in
ifferential follow-up for mortality outcomes, because vital
tatus information is obtained in both ICD recipients and
ontrol subjects in a similar manner. Finally, we did not
xamine continuous clinical data (e.g., laboratory test re-
ults) and varying levels of severity of comorbidities, becausehe majority of comorbidity data available in administrative
atabases are binary in nature (present or absent). Such data
ould potentially improve modeling of outcome events and
redictive model performance.
onclusions
n this community-based examination of ICD recipients,
e found that the presence of noncardiac comorbidities and
rior clinical HF were significant predictors of death in ICD
ecipients. Increased age was associated with comorbidities,
nd ICD recipients in older age groups had worse survival
han their younger counterparts. Our findings suggest that
reater attention to noncardiac comorbidities and HF status
ay assist in the decision to implant an ICD, and may
mprove outcomes in ICD recipients. Further research is
eeded to better characterize HF and other comorbidities as
otential determinants of outcome.
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